Determination of Circulating Placental Biomarkers Levels to Predict the Pregnancy Outcome of First Trimester After IVF.

Infertility, Female Clinical Trial

Official title:

Early Prediction of First Trimester Miscarriage After IVF With Serum Circulating Placental Biomarkers: a Pilot Study to Develop a Prediction Model.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04387994
• Other study ID #: 1812-LIS-104-TS
• Status: Completed
• Start date: June 12, 2020
• Est. completion date: December 7, 2021

Study information

• Verified date: August 2022
• Source: Instituto Valenciano de Infertilidade de Lisboa
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will assess the predictive potential of circulating placental biomarkers for spontaneous miscarriage within the following month in an IVF setting. It is hypothesized that a robust algorithm including one or more of these biomarkers may allow for the accurate same-day distinction between women with a low and high risk of a spontaneous miscarriage.

Description:

Spontaneous miscarriage is the most common adverse outcome in the first trimester of pregnancy. This is a particularly stressful situation for the expecting parents, since their need for a final diagnosis is frustrated for a potentially extended period on time which may span over several weeks. The emotional impact of this complication can be devastating, resulting frequently in depression and anxiety which may last for several months. In an attempt to allow for an earlier and more accurate diagnosis of first trimester miscarriage, multiple circulating placental biomarkers have been tested over last years. However, their potential usefulness in an everyday clinical setting remains unclear. The investigators propose a single-center observational prospective cohort study in an in vitro fertilization (IVF) setting. All recruited consenting patients will collect blood samples on a day of the first pregnancy test (12-14 days after embryo transfer) and at the time of the first (at 5 weeks plus 4-5 days of gestational age) and second (at 7 weeks plus 4-5 days of gestational age) ultrasound scan to determine the circulating placental biomarkers concentrations in order to predict the pregnancy outcome (spontaneous miscarriage versus evolutive pregnancy) until the first obstetrical ultrasound, performed between 11 weeks and 13 weeks plus 6 days of gestational age.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: December 7, 2021
• Est. primary completion date: December 7, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 48 Years

Eligibility

Inclusion Criteria:

• Age: =18 and <49 years old
• Body Mass Index (BMI): =18.5 Kg/m2 and <30 Kg/m2
• Pregnancy resulting from Assisted Reproductive Technologies (ART)
• Single blastocyst transfer pregnancy
• Pregnancy confirmed by blood test
• Gestational age < 6 weeks at the first US
• Signed and dated informed consent

Exclusion Criteria:

• Spontaneous pregnancies
• Treatment for prevention of miscarriage (i.e. corticoids, aspirin, heparin)
• Those unable to provide the 11th-13th week ultrasound report
• Those unable to comprehend the investigational nature of the proposed study

Related Conditions & MeSH terms

• Abortion, Spontaneous
• First Trimester Spontaneous Abortion
• Infertility
• Infertility, Female

Intervention

Other:
• Blood samples collection
Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.

Locations

Country	Name	City	State
Portugal	Instituto Valenciano de Infertilidade de Lisboa	Lisboa

Sponsors (2)

Lead Sponsor	Collaborator
Instituto Valenciano de Infertilidade de Lisboa	Roche Pharma AG

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pregnancy outcome (spontaneous miscarriage versus evolutive pregnancy) at the first trimester ultrasound	Measurement of circulating placental biomarkers levels	Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)
Secondary	Abnormal outcomes of early pregnancy (biochemical pregnancy and extra uterine pregnancy)	Measurement of circulating placental biomarkers levels	Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)
Secondary	Risk of obstetric complications/adverse outcomes for first-trimester spontaneous miscarriage	Measurement of circulating placental biomarkers levels	Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)